Sign up to save your podcasts
Or
Share Lead: Virtual reality-based Mindfulness-Oriented Recovery Enhancement (MORE-VR) as an adjunct to medications for opioid use disorder: a Phase 1 trial
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Lead: Virtual reality-based Mindfulness-Oriented Recovery Enhancement (MORE-VR) as an adjunct to medications for opioid use disorder: a Phase 1 trial
Virtual reality-based Mindfulness-Oriented Recovery Enhancement (MORE-VR) as an adjunct to medications for opioid use disorder: a Phase 1 trial 🔓
Annals of Medicine
Mindfulness-Oriented Recovery Enhancement (MORE) uses mindfulness training to address dysregulation in brain reward systems. MORE has been shown to reduce drug cue reactivity and in an RCT reduced opioid misuse 45% at 9 months. Face-to-face MORE requires significant time of trained clinicians, and this study explored the feasibility of delivering MORE by virtual reality (VR). Treatment consisted of 8 weekly, one-hour MORE-VR sessions. Patients could choose the VR setting for their meditation (beach, forest, waterfall) and interact with virtual drugs and paraphernalia during session 5, which was devoted to examining and managing craving. Of 38 patients, 68% completed 4 or more sessions and 50% completed all sessions. Opioid use decreased significantly (p =.04), as well as craving (p<.001), and results showed a significant increase in positive affect (p<.001).
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
View all episodes
By American Society of Addiction Medicine
4.9
77 ratings
Virtual reality-based Mindfulness-Oriented Recovery Enhancement (MORE-VR) as an adjunct to medications for opioid use disorder: a Phase 1 trial 🔓
Annals of Medicine
Mindfulness-Oriented Recovery Enhancement (MORE) uses mindfulness training to address dysregulation in brain reward systems. MORE has been shown to reduce drug cue reactivity and in an RCT reduced opioid misuse 45% at 9 months. Face-to-face MORE requires significant time of trained clinicians, and this study explored the feasibility of delivering MORE by virtual reality (VR). Treatment consisted of 8 weekly, one-hour MORE-VR sessions. Patients could choose the VR setting for their meditation (beach, forest, waterfall) and interact with virtual drugs and paraphernalia during session 5, which was devoted to examining and managing craving. Of 38 patients, 68% completed 4 or more sessions and 50% completed all sessions. Opioid use decreased significantly (p =.04), as well as craving (p<.001), and results showed a significant increase in positive affect (p<.001).
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM
More shows like This Week in Addiction Medicine from ASAM
View all
NEI Podcast
129 Listeners
AFP: American Family Physician Podcast
706 Listeners
Mayo Clinic Talks
281 Listeners
Frankly Speaking About Family Medicine
253 Listeners
The Curbsiders Internal Medicine Podcast
3,336 Listeners
Addiction Medicine: Beyond the Abstract
31 Listeners
Psychiatry & Psychotherapy Podcast
1,321 Listeners
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
716 Listeners
Psychopharmacology and Psychiatry Updates
290 Listeners
The Carlat Psychiatry Podcast
562 Listeners
The Curbsiders Addiction Medicine Podcast
122 Listeners
Addiction Medicine Journal Club
33 Listeners
Psychiatry Boot Camp
175 Listeners
PsychRounds: The Psychiatry Podcast
112 Listeners
ASAM Practice Pearls
17 Listeners